Pluto Bioinformatics

GSE87186: Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-nave Adults: A Randomized, Active-controlled, First-in-human Phase 1 Trial

Bulk RNA sequencing

We report a first-in-human trial evaluating safety and immunogenicity of a recombinant BCG, AERAS-422, over-expressing TB antigens Ag85A, Ag85B, and Rv3407 and expressing mutant perfringolysin.; Interpretation: The unexpected development of VZV in two of eight healthy adult vaccine recipients resulted in discontinuation of AERAS-422 vaccine development. Immunological and transcriptomal data identified correlations with the development of TB immunity and VZV that require further investigation. SOURCE: Daniel Zak (daniel.zak@cidresearch.org) - Zak Lab Center for Infectious Disease Research